BACKGROUND B-cell chronic lymphocytic leukemia is a clinically heterogeneous disease; some patients rapidly progress and die within a few years of diagnosis, whereas others have a long life expectancy with minimal or no treatment. Telomere length and telomerase levels have been proposed as prognostic factors; however, very few cases have been characterized for both parameters and no study has a...

We report a case of chronic lymphocytic leukemia with a characteristic cytogenetics finding detected by fluorescent in situ hybridization. This case has deletion in p53 gene in 50% of interphase nuclei studied in the peripheral blood and polyploidy in 30% of cells. To our knowledge polyploidy is not commonly reported with chronic lymphocytic leukemia patients.

Environmental Health Perspectives • volume 119 | number 11 | November 2011 A 469 and does not alter our conclusion that this meta-analysis provides support for an association between occupational exposure to benzene and increased risk of multiple myeloma, acute lymphocytic leukemia, and chronic lymphocytic leukemia (Vlaanderen et al. 2011). The authors declare they have no actual or potential c...

BACKGROUND In chronic lymphocytic leukemia lenalidomide causes striking immune activation, possibly leading to clearance of tumor cells. We conducted this study to investigate the mechanism of action of lenalidomide and the basis for its unique toxicities in chronic lymphocytic leukemia. DESIGN AND METHODS Patients with relapsed chronic lymphocytic leukemia were treated with lenalidomide 20 m...

Nonhuman primate antisera defining leukemia-associ ated and normal Tand B-lymphocyte-associated anti gens were used to characterize serologically the cells from acute myelomonocytic leukemia (AMML) and chronic myelogenous leukemia patients in blast crisis (CML-BC). Earlier studies demonstrated that nonhuman primate an tisera to chronic lymphocytic leukemia, acute myelogen ous leukemia, and chro...

We investigated the frequency of mutations activating RAS oncogenes in human lymphoid malignancies, including B- and T-cell-derived acute lymphoblastic leukemia, chronic lymphocytic leukemia, and non-Hodgkin lymphoma. By the polymerase chain reaction/oligonucleotide hybridization method, DNA from 178 cases was analyzed for activating mutations involving codons 12 and 61 of the HRAS, KRAS and NR...

Chronic lymphocytic leukemia (CLL) is the most commonly diagnosed type of leukemia in Western Europe and North America, and represents about 30% of all leukemias in adults. Chronic lymphocytic leukemia is a disease of the elderly, who are often in poorer general health and burdened with multiple comorbidities. These factors affect the decision making when choosing an appropriate method of treat...

In the last decade, the management of chronic lymphocytic leukemia has undergone profound changes that have been driven by an improved understanding of the biology of the disease and the approval of several new drugs. Moreover, many novel drugs are currently under evaluation for rapid approval or have been approved by regulatory agencies, further broadening the available therapeutic armamentari...

Cryptococcus neoformans is an encapsulated yeast that typically causes illness in immunocompromised hosts. Manifestations of the disease include pulmonary, Central Nervous System (CNS), and rare skeletal involvement. Optimal antifungal therapy for involvement has yet to be established. Here we present a potential regimen disseminated cryptococcal with pulmonary patient Chronic Lymphocytic Leuke...

Although treatment results for adult acute lymphoblastic leukemia (ALL) have improved considerably in the past decades, treating adult patients with relapsed/refractory acute lymphocytic leukemia (ALL) is still difficult. Adults with refractory/relapsed acute lymphocytic leukemia (ALL) processed to death rapidly associated with chemotherapy resistance, high mortality by reinduction, etc. Only 2...